An innovative method to measure immunity

T-Cell response measurement: understanding individual immune ability

Until now, antibody tests have been the typical tool used to measure the immune response to SARS-CoV-2. Both antibodies and cellular immune response act in coordination to achieve protection from viral infections.
Hyris solution overcomes the current limitations in detecting specific T Cells, using synthetic peptides to activate T Cells in-vitro. In addition to this, Hyris developed and patented a fast and scalable RT-PCR test to quantify the specific response of T Cells. This innovative and reliable solution has been at the base of a major study published on Nature Biotechnology.

Complete understanding on IMMUNE ABILITY can be achieved only with T-CELLS RESPONSE MEASUREMENT.


Until now, antibody tests have been the typical tool used to measure the immune response to SARS-CoV-2. Both antibodies and cellular immune response act in coordination to achieve protection from viral infections. Antibodies are fundamental for preventing infection, protecting from the disease, while cellular immunity is essential to eliminate virus-infected cells, therefore supporting in fighting the disease itself.

Typically, detection of antigen specific T cells to qualify the cellular immune response is performed by expensive technology, both in terms of costs, equipment and skills required.


Hyris introduces a new bKIT™
for T-Cell testing, to UNDERSTAND and MEASURE 
patients' level of CELLULAR IMMUNITY TO SARS-COV-2.


Hyris solution overcomes the current limitations in detecting specific T Cells, using synthetic peptides to activate T Cells in-vitro. In addition to this, Hyris developed and patented a fast and scalable RT-PCR test to quantify the specific response of T Cells. This innovative and reliable solution has been at the base of a major study published on Nature Biotechnology.

Contact us to know more about the latest Hyris tests

Test Workflow

HYRIS bKIT XACT (SCV2)

SARS-CoV-2 specific T-cell activation through whole blood peptides treatment

HYRIS bKIT dqTACT

Cyclokine mRNA detection, through the execution of the Real-Time RT-PCR test on the blood previously threated

Hyris solution overcomes the current limitations in detecting specific T Cells, using synthetic peptides to activate T Cells in-vitro. In addition to this, Hyris developed and patented a fast and scalable RT-PCR test to quantify the specific response of T Cells. This innovative and reliable solution has been at the base of a major study published on Nature Biotechnology.

Potential applications

Detecting INDIVIDUAL IMMUNITY to SARS-CoV-2, complementing antibody testing
Support VACCINE R&D to measure actual individual immune response over time;
Support HEALTHCARE PRACTITIONERS in protecting specific patient categories;
Support VACCINE STRATEGIES definition for health institutions and policymakers;

Future

Hyris CONCEPTUAL INNOVATION is completely disruptive in the detection of the cellular immunity and opens a WIDE RANGE OF APPLICATIONS for understanding the full immune ability.

Newsletter

Subscribe our newsletter for periodical updates about Hyris solutions.

Address


Headquarter

London

Lower Ground Floor
One George Yard
EC3V 9DF - London, UK
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Center

Milan

Viale Lancetti 19
20158 Milan, Italy

  • This email address is being protected from spambots. You need JavaScript enabled to view it.

C.so Garibaldi 60
Milano 20121, Italy
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Hyris APAC - R&D Center of Excellence

Singapore

38 19 Cecil Street #04-01
The Quadrant at Cecil
Singapore (049704)
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

US West Coast Sales Inquiries

Los Gatos

  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Social